Equities research analysts expect Portola Pharmaceuticals Inc (NASDAQ:PTLA) to report earnings of ($1.54) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Portola Pharmaceuticals’ earnings, with estimates ranging from ($1.61) to ($1.47). Portola Pharmaceuticals posted earnings of ($1.41) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 9.2%. The firm is expected to issue its next quarterly earnings report on Monday, November 5th.

On average, analysts expect that Portola Pharmaceuticals will report full year earnings of ($5.77) per share for the current fiscal year, with EPS estimates ranging from ($5.90) to ($5.57). For the next financial year, analysts anticipate that the company will post earnings of ($3.97) per share, with EPS estimates ranging from ($5.07) to ($1.39). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Portola Pharmaceuticals.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($1.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.49) by ($0.12). Portola Pharmaceuticals had a negative net margin of 1,503.29% and a negative return on equity of 111.64%. The business had revenue of $4.01 million during the quarter, compared to analyst estimates of $6.35 million. During the same period in the previous year, the company posted ($1.22) earnings per share. Portola Pharmaceuticals’s revenue was up 5.8% on a year-over-year basis.

Several equities research analysts have issued reports on the stock. BidaskClub raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 24th. ValuEngine cut shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. Oppenheimer set a $80.00 price target on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 5th. Zacks Investment Research raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 4th. Finally, Credit Suisse Group reaffirmed an “underperform” rating and set a $28.00 price target (down from $49.00) on shares of Portola Pharmaceuticals in a research note on Friday, August 10th. Four analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $51.40.

In other Portola Pharmaceuticals news, CEO William Lis sold 5,113 shares of the firm’s stock in a transaction dated Wednesday, June 6th. The shares were sold at an average price of $45.21, for a total transaction of $231,158.73. Following the sale, the chief executive officer now directly owns 222,035 shares of the company’s stock, valued at approximately $10,038,202.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.60% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in PTLA. BlackRock Inc. boosted its position in shares of Portola Pharmaceuticals by 12.5% in the second quarter. BlackRock Inc. now owns 5,251,512 shares of the biopharmaceutical company’s stock worth $198,351,000 after acquiring an additional 583,581 shares during the last quarter. Temasek Holdings Private Ltd boosted its position in shares of Portola Pharmaceuticals by 6.0% in the second quarter. Temasek Holdings Private Ltd now owns 5,174,168 shares of the biopharmaceutical company’s stock worth $195,428,000 after acquiring an additional 290,600 shares during the last quarter. Cadian Capital Management LP boosted its position in shares of Portola Pharmaceuticals by 83.7% in the second quarter. Cadian Capital Management LP now owns 2,280,201 shares of the biopharmaceutical company’s stock worth $86,123,000 after acquiring an additional 1,039,257 shares during the last quarter. Zevenbergen Capital Investments LLC boosted its position in shares of Portola Pharmaceuticals by 51.1% in the second quarter. Zevenbergen Capital Investments LLC now owns 1,253,625 shares of the biopharmaceutical company’s stock worth $47,349,000 after acquiring an additional 424,100 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS boosted its position in shares of Portola Pharmaceuticals by 9.0% in the second quarter. Kornitzer Capital Management Inc. KS now owns 1,166,721 shares of the biopharmaceutical company’s stock worth $44,067,000 after acquiring an additional 96,777 shares during the last quarter. 87.09% of the stock is currently owned by institutional investors.

Shares of Portola Pharmaceuticals stock traded down $0.57 during mid-day trading on Monday, hitting $25.02. 1,152,300 shares of the stock were exchanged, compared to its average volume of 1,329,758. Portola Pharmaceuticals has a twelve month low of $24.63 and a twelve month high of $64.56. The stock has a market capitalization of $1.93 billion, a P/E ratio of -5.32 and a beta of 1.76. The company has a debt-to-equity ratio of 0.91, a current ratio of 6.69 and a quick ratio of 6.59.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.

Further Reading: Should I follow buy, hold and sell recommendations?

Get a free copy of the Zacks research report on Portola Pharmaceuticals (PTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.